Common

Carequality Celebrates 10-Year Anniversary as Nation’s First Trusted Exchange Framework

Retrieved on: 
Tuesday, March 26, 2024
Organization, Health information exchange, Growth, Trust, Common, Public, Policy, EHR, Physician, Medical device

VIENNA, Va., March 26, 2024 (GLOBE NEWSWIRE) -- Carequality , the national-level, common interoperability trusted exchange framework to enable health information exchange between and among health information networks, celebrates 10 years since it was launched as an initiative under The Sequoia Project, a nonprofit trusted advocate for nationwide health information exchange.

Key Points: 
  • VIENNA, Va., March 26, 2024 (GLOBE NEWSWIRE) -- Carequality , the national-level, common interoperability trusted exchange framework to enable health information exchange between and among health information networks, celebrates 10 years since it was launched as an initiative under The Sequoia Project, a nonprofit trusted advocate for nationwide health information exchange.
  • Today, Carequality supports the exchange of more than 745,000,000 documents monthly across disparate technologies, geographies, and networks.
  • Carequality plays a pivotal role in supporting the Office of the National Coordinator for Health Information Technology’s (ONC’s) new Trusted Exchange Framework and Common AgreementSM (TEFCASM).
  • The Sequoia Project, in its role of Recognized Coordinating Entity® (RCE™), collaborates closely with Carequality to leverage its real-world experience in developing and operationalizing a nationwide, industry-led trusted exchange framework.

Blue Planet Unveils Industry’s Only Multi-Cloud Native OSS Platform

Retrieved on: 
Tuesday, April 9, 2024
Apps, Applications, Mobile, Wireless, Technology, Telecommunications, Software, Networks, Internet, Hardware, Data Management, Artificial Intelligence, Cloud, Google Cloud, BPO, Growth, Environment, Blue, Common, OSS, CIEN, ISSU, TCO, Senior, Kubernetes, DevOps, Commerce, BPI, BPA, CSP, Machine learning, Video game

Blue Planet , a division of Ciena (NYSE:CIEN), has launched a major enhancement to its intelligent automation software portfolio with the first-of-its-kind Blue Planet Cloud Native Platform .

Key Points: 
  • Blue Planet , a division of Ciena (NYSE:CIEN), has launched a major enhancement to its intelligent automation software portfolio with the first-of-its-kind Blue Planet Cloud Native Platform .
  • The new Blue Planet Cloud Native Platform allows CSPs to deploy individual applications independently or together to address their most important OSS modernization projects at their own pace.
  • These include the Blue Planet Inventory ( BPI ), Blue Planet Orchestration ( BPO ) and Blue Planet Assurance ( BPA ) applications, which are all readily available on the platform today.
  • “The Blue Planet Cloud Native Platform transcends the traditional approach of custom ‘spaghetti integrations’ that have shackled CSPs’ ability to be adaptable, open and agile.

Health Information Associates to Showcase Expertise and Innovations at AAPC's HealthCon 2024

Retrieved on: 
Monday, April 8, 2024
Diagnosis, Culture, AAPC, Documentation, Education, Common, Knowledge, American Academy, HIA, Health, Medical device

PAWLEYS ISLAND, S.C., April 8, 2024 /PRNewswire-PRWeb/ -- Health Information Associates (HIA), known for its expertise in healthcare compliance and coding services, announces its attendance at the American Academy of Professional Coders' (AAPC) HealthCon 2024. This event is a significant gathering for those in the healthcare industry, focusing on coding, documentation, and compliance.

Key Points: 
  • PAWLEYS ISLAND, S.C., April 8, 2024 /PRNewswire-PRWeb/ -- Health Information Associates (HIA) , known for its expertise in healthcare compliance and coding services, announces its attendance at the American Academy of Professional Coders' (AAPC) HealthCon 2024.
  • HIA's Vice President of Client Services, Brett Randolph, will present " Common Inpatient Audit Findings and How They Impact Your Facility " at HealthCon 2024.
  • HIA's involvement in HealthCon 2024 highlights its commitment to contributing to the healthcare industry by sharing valuable knowledge and insights.
  • For more information about HIA and its services, stop by Booth 234 at Healthcon, visit HIAcode.com or call 866-HIACODE.

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Retrieved on: 
Friday, March 22, 2024
Glucose, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, European Medicines Agency, Ezetimibe, Therapy, Anemia, Pain, Sinusitis, Esperion Therapeutics, Bempedoic acid, Abdominal pain, Risk, Gout, Committee, Spasm, ESPR, Back pain, ATP, Safety, Membrane protein, Fatigue, CHMP, Arthralgia, Angioedema, Cardiovascular disease, Kidney, Constipation, Death, Adverse event, Pregnancy, CLEAR, Rash, Esperies, Rupture, FDA, Molina Healthcare, Hypersensitivity, Health, Conference, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Uric acid, Pharmaceutical industry

In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.

Key Points: 
  • In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.
  • They also include new indications for primary hyperlipidemia, alone or in combination with a statin, and are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.
  • NEXLETOL and NEXLIZET are also the first oral non-statin LDL-C lowering drugs to be approved by the FDA to reduce the risk of CV events in both primary and secondary prevention patients.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Research, LYRA, Common, Bronchitis, Disease, MF, New Drug Application, COVID-19, Patient, Smell, Network congestion, CRS, United, Nasal cavity, Pharmacotherapy, Investment, Clinical trial, Therapy, Safety, Sinusitis, ESS, FDA, Food, Pharmaceutical industry

WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.  

Key Points: 
  • WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
  • LYR-220, a larger insert, is designed for CRS patients whose nasal cavity is enlarged due to previous ESS.
  • Cash, cash equivalents and short-term investments were $102.8 million as of December 31, 2023, compared to $102.6 million as of September 30, 2023.
  • The Company recorded an impairment charge of $1.6 million related to long-lived assets for the year ended December 31, 2023.

Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

Retrieved on: 
Thursday, March 21, 2024
Glaucoma, B&L, Inflammation, Common, Telecanthus, NIH, CHRO, ISTA, Allergan, Pain, Therapy, Poultry farming

FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.

Key Points: 
  • FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.
  • The Company believes its sodium channel, NaV1.7 program will be suitable for an array of eye pain indications.
  • Common acute eye pain indications include corneal foreign body damage or abrasion, acute angle closure glaucoma and post-surgical sequelae.
  • “The launch of our eye pain treatment program represents a significant milestone for the Company.

Augmedix Delivers 45% Revenue Growth and Expanded Gross Margins for Fourth Quarter of 2023

Retrieved on: 
Monday, March 18, 2024
GAAP, EPS, Common, Adjustment, Churn, Interest, Growth, Pharmaceutical industry

Total revenue was $12.7 million, slightly stronger than our January pre-announcement and an increase of 45% compared to $8.8 million.

Key Points: 
  • Total revenue was $12.7 million, slightly stronger than our January pre-announcement and an increase of 45% compared to $8.8 million.
  • Adjusted operating expenses, a Non-GAAP metric, increased 12% to $9.9 million compared to $8.8 million.
  • Cash and cash equivalents as of December 31, 2023, was $46.2 million compared to $21.3 million as of December 31, 2022.
  • ET / 1:30 p.m. PT today, Monday, March 18, 2024, to discuss its fourth quarter and full year 2023 financial results.

OBSI 2023 Annual Report released

Retrieved on: 
Friday, March 15, 2024
Crypto, CSA, Ombudsman, Risk, Common, Knowledge, Bank, Classification, Complaint, Fraud, Retail, Cryptocurrency

In 2023, OBSI responded to more than 17,000 public inquiries – a 63% year-over-year increase from the record levels reached in 2022.

Key Points: 
  • In 2023, OBSI responded to more than 17,000 public inquiries – a 63% year-over-year increase from the record levels reached in 2022.
  • In total, OBSI opened 3,050 cases in 2023, compared to last year’s record high of 1,151, representing a 165% year-over-year increase.
  • Our organization successfully met some very significant operational challenges as consumer demand for our services soared,” said Sarah Bradley, Ombudsman and CEO, OBSI.
  • In 2023, OBSI continued its practice of communicating regularly with financial services regulators about systemic issues and issues affecting multiple consumers.

First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline

Retrieved on: 
Thursday, March 14, 2024
Conference, Webcast, Patient, Common, Fats, GI, Acquisition, First wave, NIH, Gastrointestinal disease, Series, Marketing, Gastroparesis, FDA, Cystic fibrosis, Food, Digestion, Pharmaceutical industry

BOCA RATON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has acquired ImmunogenX in an all-stock transaction with the combined company focused on advancing a GI pipeline comprised of multiple, late-stage clinical assets, including latiglutenase, a potentially first-in-class, near Phase 3-ready, targeted, oral biotherapeutic for celiac disease. James Sapirstein will continue to serve as Chairman and Chief Executive Officer of First Wave BioPharma with Jack Syage, Ph.D., previously the Chief Executive Officer and Co-Founder of ImmunogenX, assuming the role of President and Chief Operating Officer of First Wave BioPharma. Dr. Syage and Dr. Chaitan Khosla will also join the board of directors of First Wave BioPharma.

Key Points: 
  • Dr. Syage and Dr. Chaitan Khosla will also join the board of directors of First Wave BioPharma.
  • First Wave BioPharma intends to license the commercial rights to latiglutenase in the United States and Canada to a strategic global pharmaceutical company which will commercialize latiglutenase following receipt of marketing approval.
  • First Wave BioPharma will also seek to secure financing commitments from a syndicate of institutional healthcare investors to fund the ongoing development of latiglutenase.
  • First Wave BioPharma will host a conference call and live audio webcast today, March 14, 2024, at 8:30 a.m.

Zuma Capital Management Nominates Five Highly Qualified, Independent Director Candidates at Presidio Property Trust

Retrieved on: 
Wednesday, March 13, 2024
Centurion, Resort, Letter, Spinal muscular atrophies, Exercise, Warrant, Trust, Telecommunications, Private law, Employment, TSR, WHEN, International, Compensated emancipation, Common stock, Research, Senior counsel, Security (finance), Retirement, UPON, Fear, Principal, PC, Assistant, Shareholder, Total shareholder return, Common, Capital, Highfields Capital Management, Axos Bank, Partner, WEB

ATLANTA, March 13, 2024 (GLOBE NEWSWIRE) -- Zuma Capital Management, LLC, which owns approximately 7.7% of the outstanding shares of the Series A Common Stock of Presidio Property Trust, Inc. (NASDAQ: SQFT) (“Presidio” or the “Company”), today issued a public letter to the Company’s stockholders announcing its nomination of five highly qualified, independent candidates; Reuben Berman, Stefani Carter, Vito Garfi, Brent Morrison and Elena Piliptchak, for election to the Company’s Board of Directors at the Company’s 2024 Annual Meeting of Stockholders.

Key Points: 
  • Learn more about Zuma Capital Management, LLC’s director candidates by visiting www.SavePresidio.com, where stockholders can download a copy of our letter and sign up for future updates on Zuma Capital Management’s campaign for boardroom change.
  • We have nominated five highly qualified, independent candidates for election to the Board, who have strong experience in commercial real estate, corporate governance and capital allocation.
  • 2 Source: Morningstar (as of March 12, 2024) and Zuma Capital Management Internal Estimates.
  • 3 Source: Morningstar (as of March 12, 2024) and Zuma Capital Management Internal Estimates.